Know when to pause

FDA is the Food and Drug Administration, the US drug regulator.

In compounding, a pharmacist or doctor prepares a custom medicine. As checked September 26, 2026, FDA says it has not approved these compounded drugs.

As of September 26, 2026, “FDA registered” does not mean FDA has approved the place or its medicines.

Ask which specific product has approval and where its record can be read.

Federal rules checked September 26, 2026, require a valid prescription before a pharmacy hands over or sends a prescription medicine.

In its reports checked September 26, 2026, FDA described false pharmacy names on labels for compounded semaglutide and tirzepatide.

Ask for the pharmacy’s name and compare it with the state permit record.

If a name or label detail does not match, keep that question open with the pharmacist before proceeding.

Each peptide product has its own storage needs; one temperature rule cannot cover them all.

Ask the pharmacist about the exact medicine’s label and the conditions needed for storage and delivery.

FDA has received reports of people getting the amount wrong with made-to-order semaglutide injections; some needed hospital care.

Take any unclear label or measurement question to the pharmacist or the clinician who wrote your prescription. Guessing is not a way to clear up the wording.

Ask how pregnancy, breastfeeding, past reactions and your other medicines affect the discussion.

Ask who handles an unexpected symptom, how to reach them and what counts as a reason to seek urgent care.

Patients can send medicine-problem reports through the FDA’s MedWatch service.

MedWatch is a reporting service. It is not a way to get emergency treatment.